A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours.
about
Kinesin-5: cross-bridging mechanism to targeted clinical therapySIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancerBeyond taxanes: the next generation of microtubule-targeting agentsMicrotubule-binding agents: a dynamic field of cancer therapeutics.Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer.A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study.Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells.Evaluation of activity and combination strategies with the microtubule-targeting drug sagopilone in breast cancer cell lines.A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors.New combination therapies with cell-cycle agentsUA62784, a novel inhibitor of centromere protein E kinesin-like proteinLevel of evidence for therapeutic drug monitoring of taxanes.Oncogenic role of kinesin proteins and targeting kinesin therapy.Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer.Mitosis as an anti-cancer drug target.Kinesin spindle protein (KSP) inhibitors in combination with chemotherapeutic agents for cancer therapy.Nuclear Eg5 (kinesin spindle protein) expression predicts docetaxel response and prostate cancer aggressiveness.Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer.A New Way to Treat Brain Tumors: Targeting Proteins Coded by Microcephaly Genes?: Brain tumors and microcephaly arise from opposing derangements regulating progenitor growth. Drivers of microcephaly could be attractive brain tumor targets.
P2860
Q21710690-209E3E94-233C-4976-8024-A22E1A943C5BQ24295146-6C96FF76-48F7-4A94-A2AA-5E54BB48A45FQ26865369-1938F0A9-37D5-42A4-B8AA-A2CB7FB03DF5Q27690249-EC76D72E-B86C-40F2-B4F2-7C224C45175DQ31049104-2C44F3C1-582F-4425-8194-5A4E9681C937Q34647484-2A8F013E-F3B3-441F-AF36-C497E2F3A93EQ35209477-8F701897-1329-485D-8DE7-5F768EC7EA5EQ35963684-3A833C01-321D-4E73-9889-2A9F6F984E32Q35971203-EFAD3B62-2636-4607-B16C-A7DBA6F00CFCQ36087894-1E1354C0-3BBE-4506-B29E-12C3B695D18EQ36737314-902CD598-A5B7-426E-B2DF-D4E48B92D263Q37081499-F9878C0F-7580-4C83-84F3-92B4537C9A98Q37788732-5758E781-E981-487D-889F-D8A0C31E1C4DQ38084376-15DC0A19-3334-4D4A-AD80-C49EE0A44727Q38099046-213FF5D0-917A-4CF4-9C7C-BE08574FC9B8Q38115166-6862196C-AE2B-4516-836E-63899F9F77F7Q38130485-41286991-2A57-4B68-98B4-6B3E0A78DBE9Q38389933-6A030DC2-A539-4651-B1DA-8C7F1D8A34ADQ47447546-64989A11-DBF7-43C8-A299-0B0E7DB372F9Q52690166-ED09031D-2C05-4CF1-8E1F-A29918FA057F
P2860
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
A phase I trial of ispinesib, ...... s with advanced solid tumours.
@ast
A phase I trial of ispinesib, ...... s with advanced solid tumours.
@en
type
label
A phase I trial of ispinesib, ...... s with advanced solid tumours.
@ast
A phase I trial of ispinesib, ...... s with advanced solid tumours.
@en
prefLabel
A phase I trial of ispinesib, ...... s with advanced solid tumours.
@ast
A phase I trial of ispinesib, ...... s with advanced solid tumours.
@en
P2093
P2860
P356
P1476
A phase I trial of ispinesib, ...... s with advanced solid tumours.
@en
P2093
A H M Reid
A S Protheroe
A Seebaran
D D Williams
J S de Bono
L R Molife
L S Vasist
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604264
P407
P50
P577
2008-03-04T00:00:00Z